搜尋結果
Phase 2 Study Shows Opdivo-Yervoy Highly Effective In Colon Cancer
Forbes· 1 日前A four-week course of dual immunotherapy prior to surgery is highly effective in treating a ...
Top Advisors Pledge $500,000 To Fund Breast Cancer Drug Therapy
Forbes· 1 日前Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than ...
信達生物在2024年美國臨床腫瘤學會(ASCO)年會口頭報告全球首創抗CLDN18.2/CD3雙特異性抗體(IBI389 ...
am730· 5 日前美國舊金山和中國蘇州2024年6月3日 /美通社/ -- 信達生物製藥集團(香港聯交所股票代碼:01801),一家致力於研發、生產和銷售腫瘤、自身免疫、代謝、眼科 ...
Astra's Enhertu delays breast cancer in patients with low HER2 levels
Reuters· 6 日前, opens new tab Enhertu was shown in a large trial to delay the growth of hormone-sensitive ...